Waters Corporation has launched new BioResolve™ Peptide and GTxResolve™ Lipid Phenyl-Hexyl+ and C18+ Columns, which are industry-first reversed-phase bioseparation columns. These columns are designed to accelerate drug development by enabling up to three times faster GLP-1 characterization and two times faster LNP component analysis. They also offer improved resolution and sensitivity for identifying impurities, addressing a critical need in biopharmaceutical testing for complex biologics like GLP-1 peptides and mRNA-based therapies.

Waters Corporation has launched new BioResolve Peptide and GTxResolve Lipid reversed-phase columns designed to significantly accelerate and improve the characterization of GLP-1 peptides, insulin, and lipid nanoparticles (LNPs). These columns offer up to three times faster GLP-1 analysis and two times faster LNP analysis with enhanced resolution and sensitivity, addressing challenges in separating similar impurities. The global availability of these columns begins on June 9, 2026, aiming to streamline biopharmaceutical development and regulatory readiness.